CSPC Pharmaceutical Group... (CSPCY)
CSPC Pharmaceutical Statistics
Share Statistics
CSPC Pharmaceutical has 2.88B shares outstanding. The number of shares has increased by -2.88% in one year.
| Shares Outstanding | 2.88B |
| Shares Change (YoY) | -2.88% |
| Shares Change (QoQ) | -1.72% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 8.03B |
| Failed to Deliver (FTD) Shares | 14.25K |
| FTD / Avg. Volume | 47.1% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 14.56 and the forward PE ratio is null. CSPC Pharmaceutical's PEG ratio is 3.44.
| PE Ratio | 14.56 |
| Forward PE | n/a |
| PS Ratio | 2.47 |
| Forward PS | n/a |
| PB Ratio | 2.84 |
| P/FCF Ratio | 37.41 |
| PEG Ratio | 3.44 |
Enterprise Valuation
CSPC Pharmaceutical has an Enterprise Value (EV) of 330.76B.
| EV / Sales | 9.56 |
| EV / EBITDA | 38.76 |
| EV / EBIT | 79.15 |
| EV / FCF | 144.7 |
Financial Position
The company has a current ratio of 2.63, with a Debt / Equity ratio of 0.02.
| Current Ratio | 2.63 |
| Quick Ratio | 2.32 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.08 |
| Debt / FCF | 0.31 |
| Interest Coverage | 296.58 |
Financial Efficiency
Return on Equity is 19.53% and Return on Invested Capital is 17.2%.
| Return on Equity | 19.53% |
| Return on Assets | 12.69% |
| Return on Invested Capital | 17.2% |
| Revenue Per Employee | $1.62M |
| Profits Per Employee | $274.45K |
| Employee Count | 21,400 |
| Asset Turnover | 0.75 |
| Inventory Turnover | 3.25 |
Taxes
| Income Tax | 1.32B |
| Effective Tax Rate | 17.82% |
Stock Price Statistics
The stock price has increased by -6.46% in the last 52 weeks. The beta is 0.64, so CSPC Pharmaceutical's price volatility has been higher than the market average.
| Beta | 0.64 |
| 52-Week Price Change | -6.46% |
| 50-Day Moving Average | 2.6 |
| 200-Day Moving Average | 2.64 |
| Relative Strength Index (RSI) | 62.23 |
| Average Volume (20 Days) | 30.25K |
Income Statement
In the last 12 months, CSPC Pharmaceutical had revenue of 34.6B and earned 5.87B in profits. Earnings per share was 2.16.
| Revenue | 34.6B |
| Gross Profit | 24.4B |
| Operating Income | 7.68B |
| Net Income | 5.87B |
| EBITDA | 8.53B |
| EBIT | 7.42B |
| Earnings Per Share (EPS) | 2.16 |
Balance Sheet
The company has 12.02B in cash and 706.9M in debt, giving a net cash position of 11.31B.
| Cash & Cash Equivalents | 12.02B |
| Total Debt | 706.9M |
| Net Cash | 11.31B |
| Retained Earnings | 26.46B |
| Total Assets | 47.87B |
| Working Capital | 16.02B |
Cash Flow
In the last 12 months, operating cash flow was 4.18B and capital expenditures -1.89B, giving a free cash flow of 2.29B.
| Operating Cash Flow | 4.18B |
| Capital Expenditures | -1.89B |
| Free Cash Flow | 2.29B |
| FCF Per Share | 0.19 |
Margins
Gross margin is 70.51%, with operating and profit margins of 22.2% and 16.98%.
| Gross Margin | 70.51% |
| Operating Margin | 22.2% |
| Pretax Margin | 21.36% |
| Profit Margin | 16.98% |
| EBITDA Margin | 24.66% |
| EBIT Margin | 22.2% |
| FCF Margin | 6.61% |
Dividends & Yields
CSPCY pays an annual dividend of $0.15, which amounts to a dividend yield of 3.11%.
| Dividend Per Share | $0.15 |
| Dividend Yield | 3.11% |
| Dividend Growth (YoY) | 28.57% |
| Payout Ratio | 77% |
| Earnings Yield | 6.87% |
| FCF Yield | 0.67% |
Analyst Forecast
Currently there are no analyst rating for CSPCY.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Dec 10, 2020. It was a forward split with a ratio of 8:5.
| Last Split Date | Dec 10, 2020 |
| Split Type | forward |
| Split Ratio | 8:5 |
Scores
| Altman Z-Score | 3.37 |
| Piotroski F-Score | 7 |